# JOINN Biologics US

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/joinn-biologics-us

- Industry: Biotechnology
- Headquarters: Richmond, US
- Website: www.joinnbio.com
- Total disclosed funding: $210M
- Latest round: Series B (Aug 6, 2021)
- Investors on record: 6

## About

Based in California, US, and founded in 2018 by Shusheng Geng and Tao He, JOINN Biologics US Inc. is a pharmaceutical company that develops innovative drugs. The company has production facilities in both China and the US with more than 400 employees worldwide. In August 2021, the company raised its latest Series B funding led by CITIC Private Equity.

The company's platform is a contract development and manufacturing organization (CDMO) that provides services across the entire drug development cycle. The company is engaged in cell line development and master cell bank (MCB) manufacturing, process and analytical development, formulation development, drug substance manufacturing, and drug product development services. The company also provides delivers packaged services for material production and investigational new drug enabling. 

The company plans to build a new facility in China that will have manufacturing capabilities of 100,00 liters of a bulk drug substance. The company also plans to build research and development and manufacturing centers in Beijing, Chongqing, and other Chinese cities.

## Funding rounds

- Series B, Aug 6, 2021, $150M — CPE Funds Management, Green Pine Capital Partners, Huagai Capital, Hongtai Aplus, Yingke Private Equity, HT Capital
- Series A, Dec 10, 2019, $60M — Huagai Capital

## Investors

- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A, Series B
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series B
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series B
- Hongtai Aplus (https://capitalatlas.ai/funds/hongtai-aplus) — Series B
- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Series B
- HT Capital — Series B